RSS

Breakthrough therapy designtion

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Roche’s Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) as a first-line treatment for people with advanced or metastatic HCC Read more

News

The Food and Drug Administration (FDA) has granted breakthrough therapy designation to GlaxoSmithKline (GSK) for its investigational B-cell mutation agent (BCMA) monoclonal antibody-drug conjugate, for relapsed and refractory multiple myeloma Read more

News

Sanofi and Regeneron Pharmaceuticals have revealed that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation status to cemiplimab (REGN2810), an investigational human, monoclonal antibody. Read more

News

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for 3,4-Methylenedioxymethamphetamine (MDMA) as a potential treatment (in combination with psychotherapy) for patients struggling with PTSD Read more

News

The FDA has granted breakthrough therapy designation to Novartis’ investigational chimeric antigen receptor T cell (CAR-T) therapy, CTL019 Read more

News

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation (BTD) to Rhythm’s setmelanotide Read more

News

CTL019, is the first personalised cellular therapy for the treatment of cancer to receive this important classification. Read more